Search for: "Mylan Pharmaceuticals"
Results 221 - 240
of 739
Sort by Relevance
|
Sort by Date
18 Aug 2017, 2:15 pm
Mylan Inc., et al.. [read post]
18 Aug 2017, 2:15 pm
Mylan Inc., et al.. [read post]
17 Jul 2017, 9:41 am
The process of lyophilization (freeze-drying) isnot intended to change the chemical structure of theactive pharmaceutical ingredient. [read post]
27 Jun 2017, 7:56 am
Pricing information has yet to be released to the public, but the company anticipates Symjepi will be priced well below Mylan’s outrageously over-priced EpiPen. [read post]
14 May 2017, 9:55 pm
Mylan Pharmaceuticals, Inc. v. [read post]
1 May 2017, 11:59 am
Late last month, pharmaceutical company Mylan announced that its manufacturing partner for the EpiPen Auto-Injector expanded a voluntary recall of certain lots of the EpiPen and EpiPen Jr. product. [read post]
18 Apr 2017, 6:52 am
Mylan, 2017 U.S. [read post]
12 Apr 2017, 9:52 am
(collectively, Novartis).The Board instituted IPRs on all claims of the ’283 patentbased on petitions filed by Torrent PharmaceuticalsLimited, Apotex, Inc. and Mylan Pharmaceuticals Inc. [read post]
12 Apr 2017, 8:44 am
Torrent Pharma, Apotex, and Mylan (Fed. [read post]
6 Apr 2017, 1:35 pm
Mylan, Inc., No. 15-1113(Fed. [read post]
12 Mar 2017, 9:28 am
Amici briefs have been filed by Apotex, Coherus (see recent Kat post), Biosimilars Council and Mylan, all supporting Sandoz. [read post]
6 Mar 2017, 9:00 am
From Mylan and their Epipen fiasco to Teva Pharmaceutical Industries Ltd, consumers are wondering when someone will step in to make this price gouging stop before drugs like the Epipen simply become unaffordable. [read post]
8 Feb 2017, 3:09 am
Alfonso Cioffi, No. 16-200 (holding prosecution history against the patentee) Civil Procedure – Personal Jurisdiction: Mylan Pharmaceuticals, et al. v. [read post]
31 Jan 2017, 8:55 pm
The question arose in ANDA litigation between patentee and NDA holder Cumberland Pharmaceuticals and Mylan. [read post]
25 Jan 2017, 11:25 pm
However, claim 27 is to “a pharmaceutical composition comprising a compound according to any one of claims 1-25 together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients” (emphasis added). [read post]
16 Jan 2017, 5:44 pm
Alfonso Cioffi, No. 16-200 (holding prosecution history against the patentee) Civil Procedure – Personal Jurisdiction: Mylan Pharmaceuticals, et al. v. [read post]
22 Dec 2016, 9:10 am
In the event that permission is granted, Actavis and Mylan have applied for permission to cross-appeal the findings on validity in relation to claims 10-12. [read post]
22 Dec 2016, 7:49 am
The defendant drug makers include: Mylan, Teva Pharmaceuticals, Citron Pharma, Heritage Pharmaceuticals, Aurobindo Pharmaceuticals, and Mayne Pharmaceuticals. [read post]
21 Dec 2016, 7:18 am
Mylan Pharmaceutical Inc. says they expect PTAB decisions on the IPRs sometime during the fourth quarter of 2017. [read post]
15 Dec 2016, 11:44 am
(Paul Buckowski / Times Union) Heritage Pharmaceuticals, Aurobindo Pharma USA, Citron Pharma, Mayne Pharma, Mylan Pharmaceuticals and Teva Pharmaceuticals USA are being targeted by the lawsuit. [read post]
